Recent federal actions have immediately moved FDA-approved marijuana products and those under state medical programs from Schedule I to Schedule III of the Controlled Substances Act, effective late April 2026, following a December 2025 executive order directing expedited review. The DEA has withdrawn prior proceedings and launched a new, accelerated administrative hearing on broader rescheduling—including recreational cannabis—to begin June 29 and conclude no later than July 15, 2026. This compressed timeline, aligned with firm procedural deadlines, now shapes trader assessments of when full rescheduling could take effect. The process remains subject to standard rulemaking requirements, potential public input, and legal review, leaving room for adjustments before any final rule is published.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour$758,915 Vol.
31 mars 2026
30 juin
2%
31 décembre
24%
$758,915 Vol.
30 juin
$337,208 Vol.
2%
31 décembre
$156,825 Vol.
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent federal actions have immediately moved FDA-approved marijuana products and those under state medical programs from Schedule I to Schedule III of the Controlled Substances Act, effective late April 2026, following a December 2025 executive order directing expedited review. The DEA has withdrawn prior proceedings and launched a new, accelerated administrative hearing on broader rescheduling—including recreational cannabis—to begin June 29 and conclude no later than July 15, 2026. This compressed timeline, aligned with firm procedural deadlines, now shapes trader assessments of when full rescheduling could take effect. The process remains subject to standard rulemaking requirements, potential public input, and legal review, leaving room for adjustments before any final rule is published.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Marché ouvert : Feb 7, 2026, 5:04 PM ET
Volume
$758,915Date de fin
31 mars 2026Marché ouvert
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.Recent federal actions have immediately moved FDA-approved marijuana products and those under state medical programs from Schedule I to Schedule III of the Controlled Substances Act, effective late April 2026, following a December 2025 executive order directing expedited review. The DEA has withdrawn prior proceedings and launched a new, accelerated administrative hearing on broader rescheduling—including recreational cannabis—to begin June 29 and conclude no later than July 15, 2026. This compressed timeline, aligned with firm procedural deadlines, now shapes trader assessments of when full rescheduling could take effect. The process remains subject to standard rulemaking requirements, potential public input, and legal review, leaving room for adjustments before any final rule is published.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$758,915Date de fin
31 mars 2026Marché ouvert
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...Recent federal actions have immediately moved FDA-approved marijuana products and those under state medical programs from Schedule I to Schedule III of the Controlled Substances Act, effective late April 2026, following a December 2025 executive order directing expedited review. The DEA has withdrawn prior proceedings and launched a new, accelerated administrative hearing on broader rescheduling—including recreational cannabis—to begin June 29 and conclude no later than July 15, 2026. This compressed timeline, aligned with firm procedural deadlines, now shapes trader assessments of when full rescheduling could take effect. The process remains subject to standard rulemaking requirements, potential public input, and legal review, leaving room for adjustments before any final rule is published.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes